Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.
暂无分享,去创建一个
S. Saidha | P. Calabresi | F. Paul | H. Hartung | A. Green | T. Korn | S. Schippling | A. Brandt | C. von Gall | N. Solà-Valls | E. H. Martinez-Lapiscina | P. Albrecht | D. Fischer | L. Balk | J. Havla | O. Aktas | B. Knier | J. Button | Natalia Gonzalez Caldito | A. Heskamp | H. Zimmermann | K. Lepka | C. Berndt | Hao H Yiu | P. Küry | A. Cruz-Herranz | Peter Göttle | Praveena Manogaran | M. Stettner | Anne K. Mausberg | N. Goebels | Christine Baksmeier | V. Koska | Christina Hecker | A. Mausberg | Michael Dietrich | Andrea Issberner | A. Hilla | Angelika Hallenberger | J. Steckel | E. Olbert | N. Caldito | E. Martinez-Lapiscina | Hao H. Yiu | Andrés Cruz-Herranz | Núria Solà-Valls
[1] Michael Dietrich,et al. Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. , 2019, Journal of visualized experiments : JoVE.
[2] S. Saidha,et al. The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis , 2018, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[3] S. Kusunoki,et al. 4-Aminopyridine ameliorates relapsing remitting experimental autoimmune encephalomyelitis in SJL/J mice , 2018, Journal of Neuroimmunology.
[4] X. Montalban,et al. Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond , 2018, CNS Drugs.
[5] H. Hartung,et al. Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model , 2018, Journal of Neuroinflammation.
[6] H. Schöler,et al. Nfat/calcineurin signaling promotes oligodendrocyte differentiation and myelination by transcription factor network tuning , 2018, Nature Communications.
[7] P. Brugger,et al. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years , 2018, Journal of Neurology.
[8] A. Lovett-racke,et al. Suppression of Inflammatory Demyelinaton and Axon Degeneration through Inhibiting Kv3 Channels , 2017, Front. Mol. Neurosci..
[9] H. Hartung,et al. Iron‐sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia , 2017, Glia.
[10] F. Paul,et al. Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension , 2017, Journal of Neurology.
[11] C. Heesen,et al. Pattern of gray matter volumes related to retinal thickness and its association with cognitive function in relapsing–remitting MS , 2016, Brain and behavior.
[12] M. Noble,et al. 4‐Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury , 2016, EMBO molecular medicine.
[13] Andrés Cruz-Herranz,et al. Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide , 2016, BMJ Open Ophthalmology.
[14] Pablo Villoslada,et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies , 2016, Neurology.
[15] C. Gasperini,et al. Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial , 2016, Multiple sclerosis.
[16] Jerry L Prince,et al. Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials , 2015, Multiple sclerosis international.
[17] F. Bethoux,et al. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials , 2015, Multiple sclerosis.
[18] H. Wiendl,et al. 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis , 2013, Experimental Neurology.
[19] A. Conger,et al. Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy , 2013, Neurology.
[20] Axel Petzold,et al. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment , 2012, PloS one.
[21] A. Schnitzler,et al. Optical Coherence Tomography in Parkinsonian Syndromes , 2012, PloS one.
[22] D. Centonze,et al. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis , 2012, British journal of pharmacology.
[23] Amy Conger,et al. The Impact of Utilizing Different Optical Coherence Tomography Devices for Clinical Purposes and in Multiple Sclerosis Trials , 2011, PloS one.
[24] M. Esiri,et al. Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model. , 2011, Brain : a journal of neurology.
[25] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[26] D. Herr,et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation , 2010, Proceedings of the National Academy of Sciences.
[27] H. Hartung,et al. Activation of CXCR7 receptor promotes oligodendroglial cell maturation , 2010, Annals of neurology.
[28] L. Krupp,et al. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis , 2010, Annals of neurology.
[29] D. Fischer,et al. A Method for Preparing Primary Retinal Cell Cultures for Evaluating the Neuroprotective and Neuritogenic Effect of Factors on Axotomized Mature CNS Neurons , 2010, Current protocols in neuroscience.
[30] D. Fischer,et al. Neuroprotective and Axon Growth-Promoting Effects following Inflammatory Stimulation on Mature Retinal Ganglion Cells in Mice Depend on Ciliary Neurotrophic Factor and Leukemia Inhibitory Factor , 2009, The Journal of Neuroscience.
[31] De-Pei Li,et al. Aminopyridines Potentiate Synaptic and Neuromuscular Transmission by Targeting the Voltage-activated Calcium Channel β Subunit*♦ , 2009, The Journal of Biological Chemistry.
[32] L. Krupp,et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial , 2009, The Lancet.
[33] A. Cross,et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study , 2007, Multiple sclerosis.
[34] R. Douglas,et al. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. , 2004, Investigative ophthalmology & visual science.
[35] Lin Chen,et al. Transcriptional regulation by calcium, calcineurin, and NFAT. , 2003, Genes & development.
[36] O. McManus,et al. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. , 2002, Biochemistry.
[37] C. Polman,et al. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. , 1993, Clinical neuropharmacology.
[38] S. Thanos,et al. Intravitreal injections of neurotrophic factors support the survival of axotomized retinal ganglion cells in adult rats in vivo , 1993, Brain Research.
[39] H. Korn,et al. Mechanism of 4-aminopyridine action on voltage-gated potassium channels in lymphocytes , 1992, The Journal of general physiology.
[40] D. Nicholls,et al. Repetitive Action Potentials in Isolated Nerve Terminals in the Presence of 4‐Aminopyridine: Effects on Cytosolic Free Ca2+ and Glutamate Release , 1989, Journal of neurochemistry.
[41] G. Gibson,et al. Changes in cytosolic free calcium with 1,2,3,4-tetrahydro-5-aminoacridine, 4-aminopyridine and 3,4-diaminopyridine. , 1988, Biochemical pharmacology.
[42] T A Sears,et al. The effects of 4‐aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. , 1981, The Journal of physiology.
[43] Francesco Viola,et al. The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients , 2019, Multiple sclerosis.
[44] D. Reich,et al. Multiple Sclerosis , 2018, The New England journal of medicine.
[45] Andrew M. Johnson,et al. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS. , 2017, Multiple sclerosis and related disorders.